CLIA Waiver and Dual 510(k) CLIA Waiver Submissions to FDA Workshop (Chicago, United States - August 16th-17th, 2018)

News provided by

Aug 10, 2018, 14:30 ET

DUBLIN, Aug. 10, 2018 /PRNewswire/ --

The "CLIA Waiver and Dual 510(k) CLIA Waiver Submissions to FDA" conference has been added to ResearchAndMarkets.com's offering.

CLIA Waiver applications declined significantly after FDA's CLIA Waiver guidance was published on January 30, 2008. Between 2008 and 2012, FDA reviewed 34 applications for CLIA Waiver and approved 14, sometimes taking years to issue a denial. The cost of performing CLIA Waiver studies, combined with the lengthy review times and likelihood of failure, discouraged companies from bringing new innovations to this critical public health sector.

As a result of MDUFA III, passed by Congress in 2012, FDA began accepting and reviewing Dual 510(k) and CLIA Waiver by Applications, and more companies are taking advantage of this new Dual Pathway, which promises shorter review time and higher success rates. Additionally, the 21st Century Cures Act Directs FDA to revise the section on Accuracy in the CLIA Waiver Guidance by the end of 2017. How will these changes impact CLIA Waiver Application outcomes?

You will leave this one and one-half day workshop knowing how to submit either a CLIA Waiver Application or a Dual 510(k) Waiver Application that conforms to FDA's CLIA Waiver guidance. You will learn how to design risk-based flex studies, and develop cost-saving product development and clinical study strategies. We will review FDA's CLIA categorization criteria and examine ways to incorporate simple and negligible chance of erroneous results into product design.

You will understand how CLIA Waiver requirements have evolved, how the FDA determines performance requirements for CLIA Waiver, what to expect during their review and how to maximize your chances for a successful CLIA Waiver application. Finally, you will gain insights on what to expect from the anticipated new, revised CLIA Waiver guidance.

Learning Objectives:

Upon completing this course participants should be confident in their ability to:

Understand and follow FDA's 2008 CLIA Waiver Guidance
Prepare an effective Pre-Submission for a CLIA Waiver of Dual 510(k) Waiver
Use the CLIA test complexity scoring criteria
Integrate human factors into device design
Design and execute Flex studies based on risk analysis
Design and execute CLIA Waiver or Dual Path clinical studies
Design and execute studies to evaluate performance at clinical decision points
Perform and present statistical analysis of data, including ATE and LER
Develop compliant labeling for CLIA Waived products
Prepare a CLIA Waiver or a Dual 510(k) Waiver Application
Avoid costly mistakes
Maximize the chances for a successful CLIA Waiver application

Who Should Attend:

This course is designed for people who are planning to undertake CLIA Waived product development, and people who will be involved in the supporting studies and submission of applications for CLIA Waiver to FDA. The course will address all levels of interest, from executive to technical and clerical.

Personnel who will benefit from attending this course include:

Executives and Senior managers
R&D
Design engineers
Regulatory professionals
Project managers
Risk management professionals
Clinical research professionals

For more information about this conference visit https://www.researchandmarkets.com/research/pgsgl3/clia_waiver_and?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets